Consenso multidisciplinario de cribado y diagnóstico de enfermedad pulmonar intersticial (EPI) asociada a enfermedades reumáticas autoinmunes sistémicas (ERAS)
Authors:
- Sara VargasSVSara Vargas
- Mayra Castillo JuradoMJMayra Castillo Jurado
- Maria Belen NoboaMNMaria Belen Noboa
- Carlos EncaladaCECarlos Encalada
- Gabriela GarcíaGGGabriela García
- Santiago GuzmánSGSantiago Guzmán
- José MartínezJMJosé Martínez
- Ivonne QuezadaIQIvonne Quezada
- María Amada Barcia CansinoMCMaría Amada Barcia Cansino
- Franklin UguñaFUFranklin Uguña
- Andres ZuñigaAZAndres Zuñiga
- Cesar DelgadoCDCesar Delgado
Open Access
- 1 December 2025
- journal article
- Published by Asociacion Latinoamericana de Torax in Respirar
- Vol. 17 (4) , 492-503
Abstract
Introduction: Interstitial lung disease (ILD) is a common and high-impact manifestation in patients with systemic autoimmune rheumatic diseases (SARDs). Timely detection requires clinical tools based on evidence and multidisciplinary consensus. Methods: A multidisciplinary team developed the consensus for the screening and diagnosis of ILD-SARDs through the formulation of PICO clinical questions, a systematic literature review (2017–2023) reported in accordance with the PRISMA statement, evaluation of the evidence using the GRADE system, and the formulation of clinical practice recommendations, which were validated using the Delphi methodology. Results: Twelve key recommendations were established for the screening and diagnosis of interstitial lung disease (ILD) in patients with Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE), Sjögren’s Syndrome (SS), Mixed Connective Tissue Disease (MCTD) and Idiopathic Inflammatory Myopathies (IIM). The use of high-resolution computed tomography (HRCT) and pulmonary function tests is highlighted as fundamental diagnostic tools. Respiratory assessment is recommended at each visit, along with active surveillance of fibrotic progression risk in diagnosed patients. Routine lung biopsy is not suggested, except in cases of suspected malignancy or discordant diagnoses. Conclusion: The implementation of evidence-based recommendations for the screening and diagnosis of ILD-SARDs aims to improve early detection, multidisciplinary intervention and patient prognosis. Their adoption can help standardize clinical practices and optimize care across all levels of the healthcare system.Keywords
This publication has 33 references indexed in Scilit:
- Interdisciplinary Diagnosis and Management of Patients With Interstitial Lung Disease and Connective Tissue DiseaseChest, 2024
- A Risk Score to Detect Subclinical Rheumatoid Arthritis–Associated Interstitial Lung DiseaseArthritis & Rheumatology, 2022
- Screening value of lung ultrasound in connective tissue disease related interstitial lung diseaseHeart & Lung, 2022
- Recomendaciones SER-SEPAR para el manejo de la enfermedad pulmonar intersticial difusa asociada a la artritis reumatoide. Parte 2: tratamientoReumatología Clínica, 2022
- 2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue diseaseRespiratory Investigation, 2021
- Evaluation of serum interleukin-6 (IL-6), IL-13, and IL-17 levels and computed tomography finding in interstitial lung disease associated with connective tissue disease patientsClinical Rheumatology, 2021
- Interstitial Lung Disease Associated with Connective Tissue Diseases2021
- Multimodality imaging in connective tissue disease-related interstitial lung diseaseClinical Radiology, 2021
- Screening High‐Resolution Computed Tomography of the Chest to Detect Interstitial Lung Disease in Systemic Sclerosis: A Global Survey of RheumatologistsArthritis & Rheumatology, 2018
- Sistema GRADE, evaluación sistemática y transparenteReumatología Clínica, 2018